Articles from Fellow Health

Fellow Health, a leading company focused on advancing male reproductive health through patient-centric testing solutions, today announced that industry executive and private equity advisor Paul Kappelman has been appointed Independent Chairman of the Board. Mr. Kappelman brings more than 30 years of healthcare leadership experience, including deep expertise in fertility care, to support Fellow Health in its next phase of growth.

Fellow Health, a leading company focused on advancing male reproductive health through patient-centric testing solutions, today announced it is joining the Progyny network to support the growing need for semen analysis as a critical step in the fertility care journey. Fellow Health’s mail-in semen analysis will be a covered benefit for eligible Progyny members, giving patients access to convenient, at-home testing with results equivalent to traditional in-clinic testing.

Fellow Health, a leading company focused on advancing male reproductive health through patient-centric testing solutions, today announced that it received a high-complexity laboratory permit from the New York State Department of Health (NYSDOH) Clinical Laboratory Evaluation Program (CLEP) along with approval for its post-vasectomy semen analysis (PVSA). This milestone allows Fellow Health to offer its validated PVSA test in New York.

Fellow Health, a leading company focused on advancing male reproductive health through patient-centric testing solutions, announced today the close of a $24 million Series B financing round. The round was led by 5AM Ventures, with new participation from The Forest Road Company (Forest Road). The Series B adds to Fellow Health’s prior Series A and follow-on funding, bringing the company’s total capital raised to $48 million across all rounds.

Fellow Health, a company focused on advancing male reproductive health through patient-centric testing solutions, today announced the presentation of four posters at the American Urological Association (AUA) 2025 meeting, taking place April 26–29 in Las Vegas. The studies highlight mail-in semen analysis as a potential post-PSA reflex test as well as an alternative to in-clinic post-vasectomy semen analysis (PVSA).

Fellow Health, a company focused on advancing male reproductive health through patient-centric testing solutions, today announced the findings of a study demonstrating the effectiveness of its mail-in postvasectomy semen analysis (PVSA) kits. The research, published in the Journal of Urology, found that Fellow Health’s mail-in testing significantly improves compliance rates, addressing longstanding challenges in verifying vasectomy success.

Fellow Health, a company focused on advancing male reproductive health through patient-centric testing solutions, announced today the publication of a study titled “Tissue of origin characterization of cell free DNA in seminal plasma: Implications for new liquid biopsies” in PLOS One. The research shows that seminal plasma is a rich source of cell free DNA (cfDNA) from somatic cells and provides new insights into its potential as a liquid biopsy for several conditions.

Fellow Health, a company focused on advancing male reproductive health through patient-centric testing solutions, recently achieved a significant milestone of delivering more than 100,000 patient test results since its product launch in 2020, highlighting its power to provide accurate and user-friendly testing for the male reproductive system.